BioPharm Insight, the premier source for exclusive breaking news and forward-looking analysis about drug development and forecasting data, today released its 2014 third quarter report on CRO activity, revealing that although the volume of clinical trials increased over the same quarter in 2013, the number of trials conducted in North America going from 48 percent to just 43 percent of the total year to year. The quarterly report also reveals key CRO opportunities, financing and likely IPOs that are imminent within pharmaceutical and biotech sectors.

“BioPharm Insight's third quarter report on CRO activity is just one example of how BioPharm Insight is an indispensable resource for sector analysis and key service opportunities,” said BioPharm Insight Editor-in-Chief Querida Anderson. “We’re covering all the most pertinent trial, partnership and development stories to help propel our readers’ success.”

According to the third quarter report, the number of studies scheduled to start during the quarter were 1,983 globally, an eight percent increase over the same quarter in 2013, which numbered 1,832. The largest segment was attributable to Phase II trials in 2014 and 2013, 29% and 28%, respectively. Also included in the report is extensive reporting by the BioPharm Insight editorial team, including the news that Inovio Pharmaceuticals (NASDAQ: INO) is interested in CRO and CMO offers for a Phase III cervical dysplasia trial, and Cellular Biomedicine Group (NASDAQ: CBMG) is seeking CROs to handle data management aspects of a future Phase III trial testing of ReJoin, its stem cell therapy in knee osteoarthritis. These and other opportunities for CROs are included in the BioPharm Insight quarterly report.

To read the entire BioPharm Insight 3Q14 CRO report, click here: here.

About Infinata’s BioPharm Insight

BioPharm Insight is Infinata’s flagship intelligence solution for the global healthcare markets. With its dedicated team of more than a dozen investigative journalists, BioPharm Insight delivers forward-looking, proprietary intelligence to its subscribers every day. BioPharm Insight’s editorial team covers life sciences from offices in New York and London. Featuring a comprehensive BioPharm Solutions Suite, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of the Mergermarket Group. For more information, click here.